Targeting vascular endothelial growth factor in renal cell carcinoma.
Renal cancer is the most lethal of all urological malignancies with overall 5-year survival rates of around 60%. The predominant reason for the poor prognosis of this cancer has been the relative lack of effective systemic therapy for advanced metastatic disease. Until recently immunotherapy with in...
Main Authors: | Patel, N, Muneer, A, Blick, C, Arya, M, Harris, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Vascular endothelial growth factor expression in renal cell carcinoma
by: Mohtarrudin, Norhafizah, et al.
Published: (2018) -
Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
by: Brown, J, et al.
Published: (2024) -
Sirolimus Toxicity and Vascular Endothelial Growth Factor Release From Islet and Renal Cell Lines
by: Laugharne, M, et al.
Published: (2007) -
Partial nephrectomy for renal cell carcinoma in single kidneys
by: Henderson, A, et al.
Published: (2008) -
Ex−vivo partial nephrectomy and renal autotransplantation for complex renal malignancies in the solitary kidney
by: Patel, N, et al.
Published: (2015)